克伦特罗对大鼠肝脏氮代谢及IGF-I水平的影响

目的探讨克伦特罗(CL)影响机体物质代谢的有关肝脏机制.方法利用大鼠离体肝脏灌流技术测定CL对肝脏灌流液中尿素氮水平,肝组织谷丙转氨酶(GPT)活性以及肝脏胰岛素样生长因子I(IGF-I)合成和分泌的影响.结果CL可使大鼠离体肝脏产生的尿素氮浓度下降,并有一定的剂量效应和时间效应.在给药后灌流的1、2、3、4h内1×10-6 mol/L的CL使大鼠肝脏产生的尿素氮分别下降15.02% (P>0.05)、17.97% (P>0.05)、26.76%(P<0.05)和30.08%(P<0.01),1×10-8mol/L的CL具有类似的效应.CL抑制大鼠肝组织中GPT的活性,×10-6mol/L的CL使得肝组织中GPT活性下降24.65%(P<0.05).CL还影响大鼠离体肝脏IGF-I的生成和分泌,×10-6 mol/L CL使大鼠肝组织内IGF-I的含量比对照组升高19.77%(P<0.05),灌流液中IGF-I的水平也呈增加的趋势.结论CL可通过增加对肝脏氮的储留及增强肝脏IGF-1的合成和分泌而促进机体的物质代谢.     

半胱胺对鹅胰液分泌及胰酶活性的影响

目的 :研究半胱胺对鹅胰液分泌及胰酶活性的影响。方法 :12只装有胰腺～十二指肠长久性瘘管的成年鹅。试验采用自身对照 ,试验期在日粮中一次性添加半胱胺 (10 0mg/kgbw)。连续收集计量胰液并测定胰酶活性。 结果 :①半胱胺使鹅胰液的分泌速率较对照期显著上升 (2 4 0 .16 % ,P <0 .0 1) ,其中白天升高 2 34.4 5 % ,夜间增高了2 5 3.70 %。②试验期单位容积胰蛋白酶的活性较对照期升高了 4 9.0 5 % (P <0 .0 1) ,而胰脂肪酶和胰淀粉酶的活性却较对照期分别降低了 2 5 .4 4 %和 2 1.95 % ,且变化幅度具有昼夜的差别。③试验期胰腺每小时分泌胰蛋白酶、胰脂肪酶和胰淀粉酶的总活性较对照期分别升高 4 0 6 .88% (P <0 .0 1)、15 3.5 8% (P <0 .0 1)和 16 6 .5 9% (P<0 .0 1) ,白天增加的幅度较夜晚大。结论 :半胱胺能促进鹅胰液的分泌 ,增加胰液中蛋白酶、脂肪酶和淀粉酶分泌的总量 ,从而提高鹅对饲料的消化能力 ,适应机体生长对营养的需求     

兔不同急性肝衰竭模型的建立与评价

目的:探讨一种理想的急性肝衰竭(AHF)模型建立方法.方法:36只实验兔随机分为3组:①改良药物手术诱导组(A组,n=12),先用D-氨基半乳糖(D-Gain)和脂多糖(LPS)腹腔注射,同时加用乳果糖,注射后2h以氟烷作为麻醉剂,切除约50%肝脏组织.术中经肝静脉注入5%葡萄糖氯化钠溶液10ml/kg体重;②传统手术诱导组(B组,n=12),切除约95%肝脏组织,术中不行肝静脉穿刺注射5%葡萄糖氯化钠溶液;③药物诱导组(C组,n=12),用D一氨基半乳糖(D-Gain)和脂多糖(LPS)一次性腹腔注射.比较建模死亡率、建模后24h兔存活率、血谷丙转氨酶(ALT)、血氨(NH3)、总胆红素(TB)和血糖(BS).结果:B组手术死亡率高于A组死亡率(41.77%vs0%),A组、B组兔建模成功后24h存活率及C组兔建模成功后72h存活率分别为0%,0%,25%,A组ALT和NH3水平显著高于C组(P＜0.05),TB和BG水平低于C组,但差异无显著性.结论:通过改进的50%肝切除术可建立较理想的兔AHF模型,以氟烷作为麻醉剂,药物诱导注射同时加用乳果糖,术中经中叶肝静脉注入5%葡萄糖氯化钠溶液可减少手术死亡率.     

犬肝动脉介入性热疗的安全性

经犬肝动脉灌注入 60℃生理盐水 1 80ml,持续 3 0min。观察、比较热灌注前后肝脏穿刺活检及肝、肾功能的动态变化情况。结果是 ,①谷丙转氨酶 (ALT)、谷草转氨酶 (AST)于灌注后 2 4h开始升高 ,72h达到高峰 (P <0 0 1 ) ,1 68h后逐渐下降 ,2 1 6h后恢复正常 ,总胆红素 (T BIL)、白蛋白 (ALB)、γ GT无明显变化 (P >0 0 5 ) ;②肝组织可见一过性淋巴细胞浸润、肝细胞混浊肿胀 ,1 68h后恢复正常 ;③肾功能尿素氮 (BUN)、肌苷 (Cr)无显著性变化 (P >0 0 5 ) ,尿酸 (UA)呈一过性增高 (P <0 0 5 )。结果说明 ,经肝动脉60℃灌注液介入性热疗对犬肝组织有一过性损伤 ,对肝、肾功能呈一过性影响     

移植途径对大鼠骨髓间充质干细胞归巢及肝功能恢复的影响

目的 探讨移植途径对骨髓间充质干细胞（MSCs）归巢及促进肝切除大鼠肝再生的影响.方法 建立肝切除大鼠模型,随机分为3 组,即肝切除对照组、尾静脉移植组和门静脉移植组.移植组分别经尾静脉和门静脉注射DAPI 标记的MSCs 约1.5×106/ 只,分别于第3 天和第9 天后采血清检测肝功能,第9 天处死大鼠取肝脏标本,并通过荧光显微镜观察两种移植途径对MSCs 向肝脏迁移的影响.结果 门静脉移植组（18.1 ± 3.4）个细胞/100 倍视野到肝脏归巢及定植的 MSCs 多于尾静脉移植组（7.6 ± 2.0）个细胞/100 倍视野,差异有统计学意义（P 〈 0.01）.术后第9 天各组大鼠肝功能均有好转,丙氨酸氨基转移酶（ALT）及天冬氨酸氨基转移酶（AST）3 组之间对比差异无统计学意义（F = 2.822,1.046,P = 0.057,0.365,P 〉 0.05）;但两移植组与单纯肝切除组比较血浆白蛋白（ALB）均有明显升高,差异具有统计学意义（F = 6.259,P = 0.006）;尾静脉移植组与门静脉移植组两移植组之间相比,差异无统计学意义（P 〉 0.05）.结论 移植途径对 MSCs 归巢、定植到肝脏有一定影响,门静脉途径优于外周静脉,MSCs 移植对肝大部切除大鼠肝功能恢复具有促进作用.     

高原低氧胁迫对小鼠肝脏功能及基因表达的影响

低氧作为青藏高原最为特殊的环境因素之一,对高原动物的适应进化产生了深刻的影响。持续的低氧暴露会损伤肝脏功能,引起动物机体代谢紊乱,但连续低氧处理对子代肝脏的影响仍缺乏相关研究。本研究将成年小鼠转移至高原低氧环境(海拔3 220 m)饲养并繁殖,以常氧条件下饲养小鼠为对照,统计低氧处理小鼠(低氧第0代)及其子代(低氧第1～5代)生长数据,发现长期低氧暴露导致小鼠肝脏比重增加,肝细胞肿胀,肝索间红细胞浸润,并且子一代小鼠肝小叶出现脂肪变性。血液生化指标显示,相比于对照组(常氧第0代),低氧第0代和低氧第1代的谷丙转氨酶和谷草转氨酶水平显著上升(P <0.05);血清白蛋白、球蛋白、总胆红素和总胆固醇水平在低氧第0代中下降,低氧第1代中上升(P <0.05)。空腹注射葡萄糖和胰岛素后低氧组小鼠的葡萄糖耐受能力和胰岛素敏感性显著减弱(P <0.05)。常氧第0代、低氧第0代及低氧第1代肝脏RNA-seq分析发现,低氧第0代和低氧第1代共有的459个差异基因显著富集在MAPK、细胞凋亡、脂质代谢和内质网等信号通路。本研究发现低氧胁迫对子代小鼠肝脏具有重要影响,此结果对肝脏低氧生...     

水杨酸钠对胰岛素抵抗大鼠胰岛素受体底物-1的影响

目的探讨抗炎药水杨酸钠对胰岛素抵抗大鼠胰岛素敏感性的影响及其作用机制。方法分别给大鼠静脉输注脂肪乳+肝素,脂肪乳+肝素+水杨酸钠和生理盐水7 h,并在输注的最后2 h,行清醒状态高胰岛素-正血糖钳夹试验,测定血浆葡萄糖、游离脂肪酸(FFA)、胰岛素和C-肽水平,检测肝脏、肌肉中胰岛素受体底物-1(IRS-1)及307位丝氨酸磷酸化的IRS-1表达。结果输注脂肪乳大鼠葡萄糖输注率(GIR)是输注生理盐水大鼠的45%,水杨酸钠可使GIR提高1.3倍(P0.01)。脂肪乳输注组大鼠肝脏及肌肉中307位丝氨酸磷酸化的IRS-1分别为生理盐水输注组大鼠的3倍和3.8倍(P0.001),输注水杨酸钠,肝脏、肌肉307位丝氨酸磷酸化的IRS-1下降45%、20%(P0.05)。结论 FFA增高引起肝脏及肌肉中307位丝氨酸磷酸化的IRS-1水平增高,可能是导致胰岛素抵抗发生的机制之一,应用水杨酸钠,大鼠肝脏及肌肉组织中IRS-1丝氨酸磷酸化水平下降,胰岛素抵抗改善。抗炎药物水杨酸钠可能通过抑制FFA引起的IRS-1丝氨酸磷酸化,而发挥改善胰岛素抵抗的作用。     

移植途径对大鼠骨髓间充质干细胞归巢及肝功能恢复的影响

目的 探讨移植途径对骨髓间充质干细胞(MSCs)归巢及促进肝切除大鼠肝再生的影响.方法 建立肝切除大鼠模型,随机分为3 组,即肝切除对照组、尾静脉移植组和门静脉移植组.移植组分别经尾静脉和门静脉注射DAPI 标记的MSCs 约1.5×106/ 只,分别于第3 天和第9 天后采血清检测肝功能,第9 天处死大鼠取肝脏标本,...     

D-半乳糖与L-谷氨酸诱导树鼩肝组织损伤

目的探究D-半乳糖与L-谷氨酸对树鼩肝组织损伤及机制。方法雄性树鼩随机分为4组:对照组(CT组)、D-半乳糖组(D组)、L-谷氨酸组(G组)、D-半乳糖组+L-谷氨酸组(D+G组),每周称量体重、计算存活率。给药8周后,心脏采血处死树鼩,4%多聚甲醛灌注固定肝,进行HE和免疫组织化学染色,检测TLR2、NF-κB和P-gp表达。结果相对于第1周,第8周D+G组树鼩体重下降。G组、D组、D+G组生存率下降,肝细胞变性、水肿、坏死、炎性细胞浸润、中央静脉、门静脉、分支胆管扩张,其中D+G组最严重。相对于CT组,D组、G组和D+G组的TLR2(P0. 05)、NF-κB(P0. 01)和P-gp(P0. 01)表达均升高;在3个处理组中,D+G组的TLR2(P0. 05)、NF-κB(P0. 01)和P-gp(P0. 01)表达显著高于D组和G组。结论 D-半乳糖、L-谷氨酸单独或联合给药均可引起树鼩肝组织损伤,联合给药损伤更严重。其机制可能涉及TLR2/NF-κB通路激活,同时P-糖蛋白代偿性增加。     

大鼠肝线粒体中的脂肪酸分析

用双 2 乙基己基酚酞酸酯 (DEHP)诱导大鼠肝过氧化物酶体增殖 ,然后用蔗糖密度梯度离心法分离大鼠肝线粒体 ,用毛细管气相色谱法测定肝线粒体中的脂肪酸含量。测定结果 :所测 1 4种脂肪酸的总量 ,青年正常组大于青年诱导组 (P <0 .0 1 ) ,青年正常组大于老年正常组 (P <0 .0 5 )。不饱和脂肪酸与脂肪酸总量的比例 ,老年诱导组大于老年正常组 (P <0 .0 5 ) ,青年正常组大于老年正常组 (P <0 .0 5 )。长链脂肪酸与脂肪酸总量的比例 ,老年正常组小于老年诱导组 (P <0 .0 5 )。结果表明 ,用DEHP诱导大鼠肝过氧化物酶体增值 ,影响肝线粒体脂肪酸正常代谢 ,使线粒体膜结构发生变化 ,这种变化 ,青年鼠与老年鼠不同     

克仑特罗对绵羊肝脏血液中IGF-Ⅰ、GH和胰岛素水平的影响

克仑特罗 (ｃｌｅｎｂｕｔｅｒｏｌ ,ＣＬ)为一种 β -肾上腺素能受体激动剂。自 80年代初发现 β -受体激动剂可促进机体生长并改变机体胴体组成以来 ,许多研究均显示 β -激动剂具促进脂肪动员、减少体脂沉积、增加氮素贮存和促进蛋白质合成等作用 ,进而调节机体的生长发育 ,因而 β -激动剂又被称为“营养分重分配剂” (Ｙａｎｇ＆ＭｃＥｌｌｉｇｏｔｔ ,1989;Ｃａｒｄｏｓｏ＆Ｓｔｏｃｋ ,1996;Ｓｍｉｔｈ ,1998)。然而机体内代谢水平在很大程度上受内分泌的调控。在对影响机体生长发育的内分泌研究中 ,越来越多的证据表明胰岛素样生长…     

Lactate uptake by the fetal sheep liver

Lactate is produced by the sheep placenta and is an important metabolic substrate for fetal sheep. However, lactate uptake and release by the fetal liver have not been assessed directly. We measured lactate flux across the liver in 16 fetal sheep at 129 (120-138) days gestation that had catheters chronically maintained in the fetal descending aorta, inferior vena cava, right or left hepatic vein, and umbilical vein. Lactate and hemoglobin concentrations and oxygen saturation were measured in blood drawn from all vessels. Umbilical venous, portal venous, and hepatic blood flow were measured by injecting radionuclide-labeled microspheres into the umbilical vein while obtaining a reference sample from the descending aorta. We found net hepatic uptake of lactate (5.0 +/- 4.4 mg/min per 100 g liver). A large quantity of lactate was delivered to the liver (94.2 +/- 78.1 mg/min per 100 g), so that the hepatic extraction of lactate was only 7.7 +/- 6.5%. Hepatic oxygen consumption was 3.18 +/- 3.3 ml/min per 100 g, and the hepatic lactate/oxygen quotient was 2.07 +/- 1.54. There was no significant correlation between hepatic lactate uptake and hepatic lactate or glucose delivery, hepatic oxygen consumption, hepatic blood flow, hepatic glucose flux, total body oxygen consumption, arterial pH, oxygen content, or oxygen saturation. There was, however, a significant correlation between hepatic lactate uptake and umbilical lactate uptake (r = 0.74, P less than 0.005) such that net hepatic lactate uptake was nearly equivalent to that produced across the umbilical-placental circulation.(ABSTRACT TRUNCATED AT 250 WORDS)     

A portal-arterial glucose concentration gradient as a signal for an insulin-dependent net glucose uptake in perfused rat liver

Since in the usual perfusion of isolated rat liver via the portal vein an insulin-dependent increase of hepatic glucose uptake could not be demonstrated, the possibility was considered that hepatic glucose uptake might not be a function of the absolute concentration of this substrate but of its concentration gradient between the portal vein and the hepatic artery. Therefore a new method was established for the simultaneous perfusion of isolated rat liver via both the hepatic artery (20-35% flow) and the portal vein (80-65% flow). When glucose was offered in a concentration gradient, 9.5 mM in the portal vein and 6 mM in the hepatic artery, insulin given via both vessels caused a shift from net glucose release to uptake. This insulin-dependent shift was not observed when glucose was offered without a gradient or with an inverse gradient, 6 mM in the portal vein and 9.5 mM in the hepatic artery. Using a portal-arterial glucose gradient as a signal the liver might be able to differentiate between endogenous and exogenous glucose.     

Chronic hepatic artery ligation does not prevent liver from differentiating portal vs. peripheral glucose delivery

Infusion of glucose into the hepatic artery blocks the stimulatory effect of the "portal signal" on net hepatic glucose uptake (NHGU) during portal glucose delivery. We hypothesized that hepatic artery ligation (HAL) would result in enhanced NHGU during peripheral glucose infusion because the arterial glucose concentration would be perceived as lower than that in the portal vein. Fourteen dogs underwent HAL approximately 16 days before study. Conscious 42-h-fasted dogs received somatostatin, intraportal insulin, and glucagon infusions at fourfold basal and at basal rates, respectively, and peripheral glucose infusion to create hyperglycemia. After 90 min (period 1), seven dogs (HALpo) received intraportal glucose (3.8 mg. kg-1. min-1) and seven (HALpe) continued to receive only peripheral glucose for 90 min (period 2). These two groups were compared with nine non-HAL control dogs (control) treated as were HALpe. During period 2, the arterial plasma insulin concentrations (24 +/- 3, 20 +/- 1, and 24 +/- 2 microU/ml) and hepatic glucose loads (39.1 +/- 2.5, 43.8 +/- 2.9, and 37.7 +/- 3.7 mg. kg-1. min-1) were not different in HALpe, HALpo, and control, respectively. HALpo exhibited greater (P < 0.05) NHGU than HALpe and control (3.1 +/- 0.3, 2.0 +/- 0.4, and 2.0 +/- 0.1 mg. kg-1. min-1, respectively). Net hepatic carbon retention was approximately twofold greater (P < 0.05) in HALpo than in HALpe and control. NHGU and net hepatic glycogen synthesis during peripheral glucose infusion were not enhanced by HAL. Even though there exists an intrahepatic arterial reference site for the portal vein glucose concentration, the failure of HAL to result in enhanced NHGU during peripheral glucose infusion suggests the existence of one or more comparison sites outside the liver.     

Prolonged treatment with the β3-adrenergic agonist CL 316243 induces adipose tissue remodeling in rat but not in guinea pig: 2) modulation of glucose uptake and monoamine oxidase activity

Beta3-adrenergic agonists are well-recognited to promote lipid mobilisation and adipose tissue remodeling in rodents, leading to multilocular fat cells enriched in mitochondria. However, effects of beta3-adrenergic agonists on glucose transport are still controversial. In this work, we studied in white adipose tissue (WAT) the influence of sustained beta3-adrenergic stimulation on the glucose transport and on the mitochondrial monoamine oxidase (MAO) activity. As one-week administration of CL 316243 (CL, 1 mg/kg/d) induces beta-adrenergic desensitization in rat but not in guinea pig adipocytes, attention was paid to compare these models. When expressing glucose uptake as nmoles of 2-deoxyglucose/100 mg cell lipids, maximally stimulated uptake was increased in adipocytes of WAT from treated rats but not from treated guinea pigs. However, basal hexose uptake was also increased in CL-treated rats and, as a consequence, the dose-dependent curves for insulin stimulation were similar in control and CL-treated rats when expressed as fold increase over basal. Insulin-induced lipogenesis was unchanged in rat or guinea pig adipocytes after CL-treatment. The glucose carriers GLUT4 and corresponding mRNA were increased in subcutaneous WAT or in brown adipose tissue (BAT) but not in visceral WAT or muscles of CL-treated rats. There was an increase of MAO activity in WAT and BAT, but not in liver, of CL-treated rats while no change was detected in guinea pigs. These findings show that only rat adipocytes, which are beta3-adrenergic-responsive, respond to chronic beta3-AR agonist by an increase of GLUT4 content and MAO activity, despite a desensitization of all beta-adrenoceptor subtypes.     

Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels

After a meal, glucagon-like peptide-1 (GLP-1) levels in the hepatic portal vein are elevated and are twice those in peripheral blood. The aim of this study was to determine whether any of GLP-1's acute metabolic effects are initiated within the hepatic portal vein. Experiments consisted of a 40-min basal period, followed by a 240-min experimental period, during which conscious 42-h-fasted dogs received glucose intraportally (4 mgxkg(-1)xmin(-1)) and peripherally (as needed) to maintain arterial plasma glucose levels at approximately 160 mg/dl. In addition, saline was given intraportally (CON; n = 8) or GLP-1 (1 pmolxkg(-1)xmin(-1)) was given into the hepatic portal vein (POR; n = 11) or the hepatic artery (HAT; n = 8). Portal vein plasma GLP-1 levels were basal in CON, 20x basal in POR, and 10x basal in HAT, whereas levels in the periphery and liver were the same in HAT and CON. The glucose infusion rate required to maintain hyperglycemia was significantly greater in POR (8.5 +/- 0.7 mgxkg(-1)xmin(-1), final 2 h) than in either CON or HAT (6.0 +/- 0.5 or 6.7 +/- 1.0 mgxkg(-1)xmin(-1), respectively). There were no differences among groups in either arterial plasma insulin (24 +/- 2, 23 +/- 3, and 23 +/- 3 microU/ml for CON, POR, and HAT, respectively) or glucagon (23 +/- 2, 30 +/- 3, and 25 +/- 2 pg/ml) levels during the experimental period. The increased need for glucose infusion reflected greater nonhepatic as opposed to liver glucose uptake. GLP-1 infusion increased glucose disposal independently of changes in pancreatic hormone secretion but only when the peptide was delivered intraportally.     

Effects of hyperglycemia on hepatic gluconeogenic flux during glycogen phosphorylase inhibition in the conscious dog

The aim of these studies was to investigate the effect of hyperglycemia with or without hyperinsulinemia on hepatic gluconeogenic flux, with the hypothesis that inhibition would be greatest with combined hyperglycemia/hyperinsulinemia. A glycogen phosphorylase inhibitor (BAY R3401) was used to inhibit glycogen breakdown in the conscious overnight-fasted dog, and the effects of a twofold rise in plasma glucose level (HI group) accompanied by 1) euinsulinemia (HG group) or 2) a fourfold rise in plasma insulin were assessed over a 5-h experimental period. Hormone levels were controlled using somatostatin with portal insulin and glucagon infusion. In the HG group, net hepatic glucose uptake and net hepatic lactate output substantially increased. There was little or no effect on the net hepatic uptake of gluconeogenic precursors other than lactate (amino acids and glycerol) or on the net hepatic uptake of free fatty acids compared with the control group. Consequently, whereas hyperglycemia had little effect on gluconeogenic flux to glucose 6-phosphate (G-6-P), net hepatic gluconeogenic flux was reduced because of increased hepatic glycolytic flux during hyperglycemia. Net hepatic glycogen synthesis was increased by hyperglycemia. The effect of hyperglycemia on gluconeogenic flux to G-6-P and net hepatic gluconeogenic flux was similar. We conclude that, in the absence of appreciable glycogen breakdown, the increase in glycolytic flux that accompanies hyperglycemia results in decreased net carbon flux to G-6-P but no effect on gluconeogenic flux to G-6-P.     

Portal glucose infusion increases hepatic glycogen deposition in conscious unrestrained rats.

It has been demonstrated in the conscious dog that portal glucose infusion creates a signal that increases net hepatic glucose uptake and hepatic glycogen deposition. Experiments leading to an understanding of the mechanism by which this change occurs will be facilitated if this finding can be reproduced in the rat. Rats weighing 275-300 g were implanted with four indwelling catheters (one in the portal vein, one in the left carotid artery, and two in the right jugular vein) that were externalized between the scapulae. The rats were studied in a conscious, unrestrained condition 7 days after surgery, following a 24-h fast. Each experiment consisted of a 30- to 60-min equilibration, a 30-min baseline, and a 120-min test period. In the test period, a pancreatic clamp was performed by using somatostatin, insulin, and glucagon. Glucose was given simultaneously either through the jugular vein to clamp the arterial blood level at 220 mg/dl (Pe low group) or at 250 mg/dl (Pe high group), or via the hepatic portal vein (Po group; 6 mg. kg(-1). min(-1)) and the jugular vein to clamp the arterial blood glucose level to 220 mg/dl. In the test period, the arterial plasma glucagon and insulin levels were not significantly different in the three groups (36 +/- 2, 33 +/- 2, and 30 +/- 2 pg/ml and 1.34 +/- 0.08, 1. 37 +/- 0.18, and 1.66 +/- 0.11 ng/ml in Po, Pe low, and Pe high groups, respectively). The arterial blood glucose levels during the test period were 224 +/- 4 mg/dl for Po, 220 +/- 3 for Pe low, and 255 +/- 2 for Pe high group. The liver glycogen content (micromol glucose/g liver) in the two Pe groups was not statistically different (51 +/- 7 and 65 +/- 8, respectively), whereas the glycogen level in the Po group was significantly greater (93 +/- 9, P < 0.05). Because portal glucose delivery also augments hepatic glycogen deposition in the rat, as it does in the dogs, mechanistic studies relating to its function can now be undertaken in this species.     

Low hepatic clearance of peptide YY (PYY) in the perfused rat liver.

The hepatic clearance rate and secretion rate mainly determine peripheral plasma concentrations of regulatory peptides released from the gastrointestinal tract. In the present study hepatic extraction of peptide YY (PYY) during a single passage was investigated in the in situ perfused rat liver excluding modulating actions of circulating hormones. During perfusion of low amounts of PYY (50, 100, 500 pmol l-1), peptide concentrations in the portal vein (5.1 +/- 4.6, 98.1 +/- 2.6, 558 +/- 13.6 pmol l-1) and in the hepatic vein (50.2 +/- 1.4, 88.6 +/- 2.2, 503 +/- 18.1 pmol l-1 was only 22.1%. PYY had no influence on hepatic glucose and lactate production, portal flow as well as bile flow and bile acid secretion at these concentrations. PYY seems to traverse the liver almost intact and reaches the target organs without any significant hepatic extraction. Concomitant studies on metabolic and excretory functions of the liver showed no effect of PYY.     

Combined effect of salinomycin and feeding on whole body glucose kinetics in sheep fed a high-concentrate diet

The aim of this study was to investigate the effects of salinomycin (SL) and feeding on whole body glucose kinetics in sheep fed a high-concentrate diet (25% orchardgrass hay and 75% commercial concentrate). Four adult sheep were fed the diet with or without 20 mg x kg(-1) diet of SL once daily for each 3 wk. The rates of glucose entry and utilization were determined before and during 3 h after feeding using a [ (13)C(6)] glucose dilution approach. Ruminal characteristics and concentrations of blood volatile fatty acids (VFA) and plasma glucose and insulin were also measured. Metabolizable energy intake was unaffected (P = 0.22) with SL. Salinomycin decreased (P = 0.06) the ratio of acetate to propionate in rumen fluid. Salinomycin increased (P = 0.01) both rates of entry and utilization of glucose, but did not affect (P > 0.10) concentrations of blood VFA or plasma glucose or insulin. Feeding caused gradual increases in concentrations of blood acetate (P < 0.01) and propionate (P = 0.01), a transient increase in plasma insulin concentration (P = 0.05), a transient decrease in plasma glucose concentration (P < 0.01), and persistent increases in both rates of glucose entry (P < 0.01) and utilization (P < 0.01). No SL x feeding interaction was observed (P > 0.10) on any measurements. We conclude that SL and feeding would have an additive effect on both rates of glucose entry and utilization without modifications with SL to feeding responses of peripheral concentrations of blood VFA, plasma glucose and insulin.